The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
AG 1879 inhibits the reaction [1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of GJA1 protein]; resveratrol inhibits the reaction [1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of GJA1 protein]
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of MAPK1 protein resveratrol inhibits the reaction [1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of MAPK1 protein]
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine binds to PTAFR protein 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of SELE mRNA 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased secretion of SELE protein
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of TNF mRNA 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased secretion of TNF protein
lysophosphatidic acid results in increased expression of ACTA2 mRNA N-(4-chlorophenyl)-1-((3-(furan-2-yl)phenyl)carbonyl)piperidine-3-carboxamide inhibits the reaction [lysophosphatidic acid results in increased expression of ACTA2 mRNA]
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of AKT1 protein]; Resveratrol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of AKT1 protein] 1-Butanol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of AKT1 protein]; exoenzyme C3, Clostridium botulinum inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of AKT1 protein]
ALOX5 protein promotes the reaction [lysophosphatidic acid results in increased abundance of Hydrogen Peroxide]; Masoprocol inhibits the reaction [ALOX5 protein promotes the reaction [lysophosphatidic acid results in increased abundance of Hydrogen Peroxide]]; zileuton inhibits the reaction [ALOX5 protein promotes the reaction [lysophosphatidic acid results in increased abundance of Hydrogen Peroxide]]
lysophosphatidic acid analog inhibits the reaction [cobaltous chloride results in increased activity of CASP3 protein]; lysophosphatidic acid inhibits the reaction [cobaltous chloride results in increased activity of CASP3 protein]
lysophosphatidic acid results in increased expression of CCL12 protein 3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid inhibits the reaction [lysophosphatidic acid results in increased expression of CCL12 protein]
lysophosphatidic acid results in increased expression of CCN2 protein N-(4-chlorophenyl)-1-((3-(furan-2-yl)phenyl)carbonyl)piperidine-3-carboxamide inhibits the reaction [lysophosphatidic acid results in increased expression of CCN2 mRNA] Simvastatin inhibits the reaction [lysophosphatidic acid results in increased expression of CCN2 protein]; Y 27632 inhibits the reaction [lysophosphatidic acid results in increased expression of CCN2 protein]
lysophosphatidic acid results in increased expression of COL1A2 mRNA N-(4-chlorophenyl)-1-((3-(furan-2-yl)phenyl)carbonyl)piperidine-3-carboxamide inhibits the reaction [lysophosphatidic acid results in increased expression of COL1A2 mRNA]
lysophosphatidic acid results in increased expression of CXCL12 protein 3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid inhibits the reaction [lysophosphatidic acid results in increased expression of CXCL12 protein]
lysophosphatidic acid results in increased expression of CXCL16 protein 3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid inhibits the reaction [lysophosphatidic acid results in increased expression of CXCL16 protein]
lysophosphatidic acid inhibits the reaction [CXCR1 protein binds to LPAR1 protein]; lysophosphatidic acid results in decreased expression of [CXCR1 protein binds to LPAR1 protein] lysophosphatidic acid results in decreased expression of CXCR1 mRNA
GNA13 mutant form inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EGFR protein]; Pertussis Toxin inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EGFR protein]; resveratrol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EGFR protein]
1-Butanol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EIF4EBP1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EIF4EBP1 protein]; 2-butanol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EIF4EBP1 protein]; exoenzyme C3, Clostridium botulinum inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EIF4EBP1 protein]
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]; 3-(2-methoxybenzylamino)-2-phenylpiperidine inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]; [[Capsaicin results in increased chemical synthesis of Lysophosphatidylcholines] which results in increased secretion of Lysophosphatidylcholines] promotes the reaction [ENPP2 results in increased chemical synthesis of lysophosphatidic acid]; [[ONO-8430506 results in decreased activity of ENPP2 protein] which results in decreased abundance of lysophosphatidic acid] which results in decreased expression of NFE2L2; [[ONO-8430506 results in decreased activity of ENPP2 protein] which results in decreased chemical synthesis of and results in decreased abundance of lysophosphatidic acid] which results in increased expression of ENPP2 mRNA; [ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid; [ENPP2 protein co-treated with Lysophosphatidylcholines] results in increased chemical synthesis of lysophosphatidic acid; [ONO-8430506 results in decreased activity of ENPP2 protein] which results in decreased abundance of lysophosphatidic acid; [ONO-8430506 results in decreased activity of ENPP2 protein] which results in decreased chemical synthesis of and results in decreased abundance of lysophosphatidic acid; arachidonyltrifluoromethane inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]; bisindolylmaleimide I inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]; Dizocilpine Maleate inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]; IL1B protein inhibits the reaction [lysophosphatidic acid results in decreased expression of ENPP2 protein]; TNF protein inhibits the reaction [lysophosphatidic acid results in decreased expression of ENPP2 protein]; U 0126 inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]; xestospongin C inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid] lysophosphatidic acid inhibits the reaction [ENPP2 mutant form results in decreased expression of MBP mRNA]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of GYPA mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; WP1066 inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]
FLT4 protein affects the reaction [lysophosphatidic acid results in increased expression of PECAM1 protein]; FLT4 protein affects the reaction [lysophosphatidic acid results in increased expression of PROX1 protein]
[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA]
L-4F peptide inhibits the reaction [lysophosphatidic acid results in increased expression of HIF1A protein]; resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of HIF1A protein] [lysophosphatidic acid results in increased expression of HIF1A protein] which results in increased expression of VEGFA mRNA; [lysophosphatidic acid results in increased expression of HIF1A protein] which results in increased expression of VEGFA protein; lysophosphatidic acid results in increased expression of HIF1A protein
MK2i peptide inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of HSPB1 protein]; SB 203580 inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of HSPB1 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of GYPA mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; WP1066 inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]
LPAR1 protein results in increased susceptibility to lysophosphatidic acid LPAR1 protein affects the reaction [lysophosphatidic acid results in increased stability of and affects the localization of NFE2L2 protein]; lysophosphatidic acid inhibits the reaction [CXCR1 protein binds to LPAR1 protein]; lysophosphatidic acid results in decreased expression of [CXCR1 protein binds to LPAR1 protein]
Endocannabinoids inhibits the reaction [lysophosphatidic acid binds to and results in increased activity of LPAR3 protein]; lysophosphatidic acid binds to and results in increased activity of LPAR3 protein
Endocannabinoids inhibits the reaction [lysophosphatidic acid binds to and results in increased activity of LPAR5 protein]; lysophosphatidic acid binds to and results in increased activity of LPAR5 protein
3-(4-dimethylamino-naphthalen-1-ylmethylene)-1,3-dihydro-indol-2-one inhibits the reaction [lysophosphatidic acid results in increased expression of LYVE1 protein] lysophosphatidic acid results in increased expression of LYVE1 mRNA; lysophosphatidic acid results in increased expression of LYVE1 protein
Hydrogen Peroxide promotes the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]; resveratrol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein] 1-Butanol inhibits the reaction [PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]; Pertussis Toxin inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]; PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]
Hydrogen Peroxide promotes the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]; resveratrol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein] 1-Butanol inhibits the reaction [PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]; Pertussis Toxin inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]; PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]
gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of MMP9 mRNA]; gefitinib promotes the reaction [resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of MMP9 mRNA]]; resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of MMP9 mRNA]; resveratrol promotes the reaction [gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of MMP9 mRNA]]
lysophosphatidic acid results in increased phosphorylation of MYL9 protein Farnesol analog inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MYL9 protein]; geranylgeraniol analog inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MYL9 protein]
LPAR1 protein affects the reaction [lysophosphatidic acid results in increased stability of and affects the localization of NFE2L2 protein]; lysophosphatidic acid results in increased stability of and affects the localization of NFE2L2 protein [[ONO-8430506 results in decreased activity of ENPP2 protein] which results in decreased abundance of lysophosphatidic acid] which results in decreased expression of NFE2L2
Pertussis Toxin inhibits the reaction [lysophosphatidic acid results in increased expression of NPPA protein]; Y 27632 inhibits the reaction [lysophosphatidic acid results in increased expression of NPPA protein]
lysophosphatidic acid results in increased activity of PAK1 protein 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [lysophosphatidic acid results in increased activity of PAK1 protein]; diphenyleneiodonium inhibits the reaction [lysophosphatidic acid results in increased activity of PAK1 protein]; Genistein inhibits the reaction [lysophosphatidic acid results in increased activity of PAK1 protein]; Pertussis Toxin inhibits the reaction [lysophosphatidic acid results in increased activity of PAK1 protein]
lysophosphatidic acid results in increased expression of PDPN mRNA; lysophosphatidic acid results in increased expression of PDPN protein 3-(4-dimethylamino-naphthalen-1-ylmethylene)-1,3-dihydro-indol-2-one inhibits the reaction [lysophosphatidic acid results in increased expression of PDPN protein]
lysophosphatidic acid results in increased expression of PECAM1 protein 3-(4-dimethylamino-naphthalen-1-ylmethylene)-1,3-dihydro-indol-2-one inhibits the reaction [lysophosphatidic acid results in increased expression of PECAM1 protein]; FLT4 protein affects the reaction [lysophosphatidic acid results in increased expression of PECAM1 protein]
1-Butanol inhibits the reaction [lysophosphatidic acid results in increased activity of PIP5K1A protein]; DGKA protein promotes the reaction [lysophosphatidic acid results in increased activity of PIP5K1A protein]
gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of PLAU mRNA]; gefitinib promotes the reaction [resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of PLAU mRNA]]; resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of PLAU mRNA]; resveratrol promotes the reaction [gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of PLAU mRNA]]
1-Butanol inhibits the reaction [PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]]; 1-Butanol inhibits the reaction [PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]]; bisindolylmaleimide I inhibits the reaction [lysophosphatidic acid results in increased activity of PLD1 protein]; Pertussis Toxin inhibits the reaction [lysophosphatidic acid results in increased activity of PLD1 protein]; PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]; PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]; toxB protein, Clostridium difficile inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of PLD1 protein]
lysophosphatidic acid results in increased phosphorylation of PPP1R12A protein Y 27632 inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of PPP1R12A protein]
lysophosphatidic acid results in increased expression of PROX1 mRNA; lysophosphatidic acid results in increased expression of PROX1 protein 3-(4-dimethylamino-naphthalen-1-ylmethylene)-1,3-dihydro-indol-2-one inhibits the reaction [lysophosphatidic acid results in increased expression of PROX1 protein]; FLT4 protein affects the reaction [lysophosphatidic acid results in increased expression of PROX1 protein]
lysophosphatidic acid results in increased phosphorylation of PTK2 protein [wortmannin co-treated with lysophosphatidic acid] results in increased phosphorylation of PTK2 protein; KNG1 protein inhibits the reaction [[wortmannin co-treated with lysophosphatidic acid] results in increased phosphorylation of PTK2 protein] [wortmannin co-treated with lysophosphatidic acid] results in increased phosphorylation of PTK2 protein; Atropine inhibits the reaction [oxotremorine M inhibits the reaction [[wortmannin co-treated with lysophosphatidic acid] results in increased phosphorylation of PTK2 protein]]; oxotremorine M inhibits the reaction [[wortmannin co-treated with lysophosphatidic acid] results in increased phosphorylation of PTK2 protein]
lysophosphatidic acid results in increased activity of RHOA protein Farnesol analog inhibits the reaction [lysophosphatidic acid results in increased activity of RHOA protein]; geranylgeraniol analog inhibits the reaction [lysophosphatidic acid results in increased activity of RHOA protein]
Farnesol analog inhibits the reaction [lysophosphatidic acid results in increased activity of RHOC protein]; geranylgeraniol analog inhibits the reaction [lysophosphatidic acid results in increased activity of RHOC protein]
lysophosphatidic acid results in increased phosphorylation of RPS6KB1 protein resveratrol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of RPS6KB1 protein] 1-Butanol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of RPS6KB1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of RPS6KB1 protein]; exoenzyme C3, Clostridium botulinum inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of RPS6KB1 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; WP1066 inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]
[lysophosphatidic acid results in increased expression of HIF1A protein] which results in increased expression of VEGFA mRNA; [lysophosphatidic acid results in increased expression of HIF1A protein] which results in increased expression of VEGFA protein resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of VEGFA protein]
[sodium arsenite co-treated with Platelet Activating Factor co-treated with Arachidonic Acid] results in increased phosphorylation of and results in increased activity of ALOX5 protein; [zileuton results in decreased activity of ALOX5 protein] inhibits the reaction [Calcimycin results in increased abundance of Platelet Activating Factor] Platelet Activating Factor results in increased expression of ALOX5 mRNA
Carbon Tetrachloride promotes the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor]; EDNRB protein affects the reaction [Carbon Tetrachloride promotes the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor]]; EDNRB protein affects the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor]
EDNRB protein affects the reaction [Carbon Tetrachloride promotes the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor]]; EDNRB protein affects the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor]
[Platelet Activating Factor co-treated with Cytochalasin B] results in increased secretion of GUSB protein; IMMLG5521 inhibits the reaction [[Platelet Activating Factor co-treated with Cytochalasin B] results in increased secretion of GUSB protein]
Platelet Activating Factor results in increased expression of IL1B mRNA Platelet Activating Factor results in increased secretion of IL1B protein [Platelet Activating Factor co-treated with MIR149 mRNA] affects the secretion of IL1B protein; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of IL1B protein]
[Platelet Activating Factor co-treated with MIR149 mRNA] affects the secretion of IL6 protein; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of IL6 protein]
Foropafant inhibits the reaction [Platelet Activating Factor results in increased expression of ITGAM protein]; Isoproterenol promotes the reaction [Theophylline inhibits the reaction [Platelet Activating Factor results in increased expression of ITGAM protein]]; Theophylline inhibits the reaction [Platelet Activating Factor results in increased expression of ITGAM protein]
Platelet Activating Factor results in increased expression of MYD88 protein PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased expression of MYD88 protein]
NCEH1 protein inhibits the reaction [[Chlorpyrifos metabolite co-treated with Cytidine Diphosphate Choline] results in increased abundance of Platelet Activating Factor]
Acetylcysteine inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; BN 50739 inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; Genistein inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; herbimycin inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; pyrrolidine dithiocarbamic acid inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; Tosylphenylalanyl Chloromethyl Ketone inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; Vitamin E inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]; BN 50730 inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]; BN 50739 inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]; CMI 392 inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]; MK 287 inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]; zileuton inhibits the reaction [Platelet Activating Factor binds to PTAFR protein] Platelet Activating Factor results in increased expression of PTAFR mRNA Platelet Activating Factor results in increased phosphorylation of PTAFR protein bepafant inhibits the reaction [Platelet Activating Factor results in increased expression of PTAFR mRNA]; Carbon Tetrachloride promotes the reaction [Platelet Activating Factor binds to PTAFR protein]; RGS4 protein inhibits the reaction [Platelet Activating Factor results in increased phosphorylation of PTAFR protein]; TNF protein affects the reaction [Platelet Activating Factor results in increased expression of PTAFR mRNA]
Platelet Activating Factor results in increased expression of PVT1 mRNA [Platelet Activating Factor co-treated with PVT1 mRNA] affects the expression of MIR149 mRNA; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased expression of MYD88 protein]; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of IL1B protein]; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of IL6 protein]; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of TNF protein]
Isoproterenol promotes the reaction [Theophylline inhibits the reaction [Platelet Activating Factor results in increased secretion of SELL protein]]; Theophylline inhibits the reaction [Platelet Activating Factor results in increased secretion of SELL protein]
Platelet Activating Factor results in increased secretion of TNF protein [Platelet Activating Factor co-treated with MIR149 mRNA] affects the secretion of TNF protein; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of TNF protein] TNF protein affects the reaction [Platelet Activating Factor results in increased expression of PTAFR mRNA] Platelet Activating Factor results in increased expression of TNF mRNA Acetylcysteine inhibits the reaction [Platelet Activating Factor results in increased expression of TNF mRNA]; BN 50739 inhibits the reaction [Platelet Activating Factor results in increased expression of TNF mRNA]; pyrrolidine dithiocarbamic acid inhibits the reaction [Platelet Activating Factor results in increased expression of TNF mRNA]; Vitamin E inhibits the reaction [Platelet Activating Factor results in increased expression of TNF mRNA]
[1,2-oleoylphosphatidylcholine co-treated with dioleoylphosphatidic acid] binds to SOD1 protein; [1,2-oleoylphosphatidylcholine co-treated with dioleoylphosphatidic acid] binds to SOD1 protein mutant form; [1,2-oleoylphosphatidylcholine co-treated with dioleoylphosphatidic acid] promotes the reaction [SOD1 protein binds to SOD1 protein]; [1,2-oleoylphosphatidylcholine co-treated with dioleoylphosphatidic acid] promotes the reaction [SOD1 protein mutant form binds to SOD1 protein mutant form]
edelfosine inhibits the reaction [Nicotine results in increased phosphorylation of BCL2 protein]; edelfosine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of BCL2 protein]; edelfosine promotes the reaction [Cytarabine results in decreased expression of BCL2 protein]
edelfosine inhibits the reaction [F2RL1 protein promotes the reaction [allyl isothiocyanate results in increased activity of TRPA1 protein]]; edelfosine inhibits the reaction [F2RL1 protein promotes the reaction [cinnamaldehyde results in increased activity of TRPA1 protein]]
edelfosine inhibits the reaction [Cytarabine affects the localization of PLCB2 protein]; edelfosine inhibits the reaction [Tetradecanoylphorbol Acetate affects the localization of PLCB2 protein]
edelfosine inhibits the reaction [F2RL1 protein promotes the reaction [allyl isothiocyanate results in increased activity of TRPA1 protein]]; edelfosine inhibits the reaction [F2RL1 protein promotes the reaction [cinnamaldehyde results in increased activity of TRPA1 protein]]
CD14 protein promotes the reaction [lipopeptidophosphoglycan results in increased activity of TLR2 protein]; CD14 protein promotes the reaction [lipopeptidophosphoglycan results in increased activity of TLR4 protein]
[lipopeptidophosphoglycan binds to and results in increased activity of TLR2 protein] which results in increased secretion of IL10 protein; [lipopeptidophosphoglycan binds to and results in increased activity of TLR4 protein] which results in increased secretion of IL10 protein
[lipopeptidophosphoglycan binds to and results in increased activity of TLR2 protein] which results in increased secretion of IL12B protein; [lipopeptidophosphoglycan binds to and results in increased activity of TLR4 protein] which results in increased secretion of IL12B protein
[lipopeptidophosphoglycan binds to and results in increased activity of TLR2 protein] results in increased activity of [NFKB1 protein binds to RELA protein]; [lipopeptidophosphoglycan binds to and results in increased activity of TLR4 protein] results in increased activity of [NFKB1 protein binds to RELA protein]
[lipopeptidophosphoglycan binds to and results in increased activity of TLR2 protein] results in increased activity of [NFKB1 protein binds to RELA protein]; [lipopeptidophosphoglycan binds to and results in increased activity of TLR4 protein] results in increased activity of [NFKB1 protein binds to RELA protein]
[lipopeptidophosphoglycan binds to and results in increased activity of TLR2 protein] results in increased activity of [NFKB1 protein binds to RELA protein]; [lipopeptidophosphoglycan binds to and results in increased activity of TLR2 protein] which results in increased secretion of CXCL8 protein; [lipopeptidophosphoglycan binds to and results in increased activity of TLR2 protein] which results in increased secretion of IL10 protein; [lipopeptidophosphoglycan binds to and results in increased activity of TLR2 protein] which results in increased secretion of IL12B protein; [lipopeptidophosphoglycan binds to and results in increased activity of TLR2 protein] which results in increased secretion of TNF protein; CD14 protein promotes the reaction [lipopeptidophosphoglycan results in increased activity of TLR2 protein]; lipopeptidophosphoglycan binds to and results in increased activity of TLR2 protein TLR2 protein results in increased susceptibility to lipopeptidophosphoglycan
[lipopeptidophosphoglycan binds to and results in increased activity of TLR4 protein] results in increased activity of [NFKB1 protein binds to RELA protein]; [lipopeptidophosphoglycan binds to and results in increased activity of TLR4 protein] which results in increased secretion of CXCL8 protein; [lipopeptidophosphoglycan binds to and results in increased activity of TLR4 protein] which results in increased secretion of IL10 protein; [lipopeptidophosphoglycan binds to and results in increased activity of TLR4 protein] which results in increased secretion of IL12B protein; [lipopeptidophosphoglycan binds to and results in increased activity of TLR4 protein] which results in increased secretion of TNF protein; CD14 protein promotes the reaction [lipopeptidophosphoglycan results in increased activity of TLR4 protein]; lipopeptidophosphoglycan binds to and results in increased activity of TLR4 protein TLR4 protein results in increased susceptibility to lipopeptidophosphoglycan
[lipopeptidophosphoglycan binds to and results in increased activity of TLR2 protein] which results in increased secretion of TNF protein; [lipopeptidophosphoglycan binds to and results in increased activity of TLR4 protein] which results in increased secretion of TNF protein
Lysophosphatidylcholines results in increased expression of CASP3 protein GPR4 protein promotes the reaction [Lysophosphatidylcholines results in increased expression of CASP3 protein]
alpha-Tocopherol inhibits the reaction [Lysophosphatidylcholines results in increased expression of CAV1 mRNA]; quercetin 3-O-glucuronide inhibits the reaction [Lysophosphatidylcholines results in increased expression of CAV1 mRNA]; Quercetin inhibits the reaction [Lysophosphatidylcholines results in increased expression of CAV1 mRNA]; Quercetin inhibits the reaction [Lysophosphatidylcholines results in increased expression of CAV1 protein] Lysophosphatidylcholines results in increased expression of CAV1 mRNA; Lysophosphatidylcholines results in increased expression of CAV1 protein
[[Capsaicin results in increased chemical synthesis of Lysophosphatidylcholines] which results in increased secretion of Lysophosphatidylcholines] promotes the reaction [ENPP2 results in increased chemical synthesis of lysophosphatidic acid]; [ENPP2 protein co-treated with Lysophosphatidylcholines] results in increased chemical synthesis of lysophosphatidic acid
Lysophosphatidylcholines results in increased ubiquitination of GJA1 protein Lysophosphatidylcholines affects the localization of and results in increased phosphorylation of GJA1 protein; PRKCE affects the reaction [Lysophosphatidylcholines results in increased phosphorylation of GJA1 protein]
Lysophosphatidylcholines results in increased expression of GPR4 mRNA; Lysophosphatidylcholines results in increased expression of GPR4 protein GPR4 protein promotes the reaction [Lysophosphatidylcholines results in increased expression of CASP3 protein]; GPR4 protein promotes the reaction [Lysophosphatidylcholines results in increased expression of IL18 protein]; GPR4 protein promotes the reaction [Lysophosphatidylcholines results in increased expression of IL1B protein]; GPR4 protein promotes the reaction [Lysophosphatidylcholines results in increased expression of IL33 protein]; GPR4 protein promotes the reaction [Lysophosphatidylcholines results in increased expression of NLRP3 protein]
Lysophosphatidylcholines results in increased expression of ICAM1 mRNA quercetin 3-O-glucuronide inhibits the reaction [Lysophosphatidylcholines results in increased expression of ICAM1 mRNA]; Quercetin inhibits the reaction [Lysophosphatidylcholines results in increased expression of ICAM1 mRNA]
Lysophosphatidylcholines results in increased expression of IL18 protein GPR4 protein promotes the reaction [Lysophosphatidylcholines results in increased expression of IL18 protein]
Lysophosphatidylcholines results in increased expression of IL1B protein GPR4 protein promotes the reaction [Lysophosphatidylcholines results in increased expression of IL1B protein]
Lysophosphatidylcholines results in increased expression of IL33 protein GPR4 protein promotes the reaction [Lysophosphatidylcholines results in increased expression of IL33 protein]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Lysophosphatidylcholines results in increased phosphorylation of MAPK1 protein]; resveratrol inhibits the reaction [Lysophosphatidylcholines results in increased phosphorylation of MAPK1 protein]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Lysophosphatidylcholines results in increased phosphorylation of MAPK3 protein]; resveratrol inhibits the reaction [Lysophosphatidylcholines results in increased phosphorylation of MAPK3 protein]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Lysophosphatidylcholines results in increased expression of NOS2 mRNA]; Resveratrol inhibits the reaction [Lysophosphatidylcholines results in increased expression of NOS2 mRNA]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Lysophosphatidylcholines results in decreased expression of NOS3 mRNA]; resveratrol inhibits the reaction [Lysophosphatidylcholines results in decreased expression of NOS3 mRNA]
Lysophosphatidylcholines results in decreased expression of PTGS1 mRNA 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Lysophosphatidylcholines results in decreased expression of PTGS1 mRNA]; resveratrol inhibits the reaction [Lysophosphatidylcholines results in decreased expression of PTGS1 mRNA]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Lysophosphatidylcholines results in increased expression of PTGS2 mRNA]; resveratrol inhibits the reaction [Lysophosphatidylcholines results in increased expression of PTGS2 mRNA]
Lysophosphatidylcholines promotes the reaction [TRPC5 protein results in increased transport of Calcium]; resveratrol inhibits the reaction [Lysophosphatidylcholines promotes the reaction [TRPC5 protein results in increased transport of Calcium]]
lysophosphatidylethanolamine analog inhibits the reaction [cobaltous chloride results in increased activity of CASP3 protein] lysophosphatidylethanolamine analog inhibits the reaction [Glycochenodeoxycholic Acid results in increased cleavage of CASP3 protein]
lysophosphatidylethanolamine analog inhibits the reaction [cobaltous chloride results in decreased expression of CFLAR mRNA] lysophosphatidylethanolamine analog results in increased expression of CFLAR protein Glycochenodeoxycholic Acid promotes the reaction [lysophosphatidylethanolamine analog results in increased expression of CFLAR protein]; lysophosphatidylethanolamine analog promotes the reaction [Glycochenodeoxycholic Acid results in increased expression of CFLAR protein] lysophosphatidylethanolamine analog results in increased expression of CFLAR mRNA; lysophosphatidylethanolamine analog results in increased expression of CFLAR protein
lysophosphatidylethanolamine analog inhibits the reaction [cobaltous chloride results in decreased expression of and results in increased degradation of MCL1 protein] lysophosphatidylethanolamine analog results in increased expression of MCL1 protein lysophosphatidylethanolamine analog inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of and results in increased degradation of MCL1 protein]
[NR5A2 gene mutant form results in increased susceptibility to Dietary Fats] which results in increased abundance of lysophosphatidylethanolamine; [NR5A2 gene mutant form results in increased susceptibility to Dietary Fats] which results in increased abundance of lysophosphatidylethanolamine analog
lysophosphatidylglycerol results in decreased activity of PON1 protein lysophosphatidylglycerol inhibits the reaction [PON1 protein results in increased hydrolysis of Paraoxon]
alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [Phosphatidic Acids results in increased phosphorylation of AKT1 protein] R 59949 inhibits the reaction [Phosphatidic Acids results in increased phosphorylation of AKT1 protein]
AVP protein results in increased abundance of Phosphatidic Acids 2-(4-amylcinnamoyl)amino-4-chlorobenzoic acid inhibits the reaction [AVP protein results in increased abundance of Phosphatidic Acids]
Phosphatidic Acids inhibits the reaction [Ethanol results in decreased phosphorylation of and results in decreased activity of MAPK1 protein]; Phosphatidic Acids results in increased phosphorylation of and results in increased activity of MAPK1 protein; U 0126 inhibits the reaction [Phosphatidic Acids results in increased phosphorylation of and results in increased activity of MAPK1 protein]
Phosphatidic Acids inhibits the reaction [Ethanol results in decreased phosphorylation of and results in decreased activity of MAPK3 protein]; Phosphatidic Acids results in increased phosphorylation of and results in increased activity of MAPK3 protein; U 0126 inhibits the reaction [Phosphatidic Acids results in increased phosphorylation of and results in increased activity of MAPK3 protein]
Phosphatidic Acids results in increased activity of MMP2 protein Quercetin inhibits the reaction [Phosphatidic Acids results in increased activity of MMP2 protein]
MTOR protein affects the reaction [Phosphatidic Acids results in increased activity of RPS6KB2 protein] Phosphatidic Acids results in increased activity of MTOR protein
[1-Butanol inhibits the reaction [PLD2 protein results in increased chemical synthesis of Phosphatidic Acids]] affects the reaction [PENK protein binds to and results in increased activity of OPRM1 protein]
[1-Butanol inhibits the reaction [PLD2 protein results in increased chemical synthesis of Phosphatidic Acids]] affects the reaction [PENK protein binds to and results in increased activity of OPRM1 protein]
1-Butanol inhibits the reaction [PLD2 protein results in increased chemical synthesis of Phosphatidic Acids]; [1-Butanol inhibits the reaction [PLD2 protein results in increased chemical synthesis of Phosphatidic Acids]] affects the reaction [PENK protein binds to and results in increased activity of OPRM1 protein]
Phosphatidic Acids results in increased activity of PRKCZ protein Phosphatidic Acids results in increased phosphorylation of and results in increased activity of PRKCZ protein
MTOR protein affects the reaction [Phosphatidic Acids results in increased activity of RPS6KB2 protein]; Sirolimus inhibits the reaction [Phosphatidic Acids results in increased activity of RPS6KB2 protein]; wortmannin inhibits the reaction [Phosphatidic Acids results in increased activity of RPS6KB2 protein]
TNF protein inhibits the reaction [Carbachol results in increased abundance of Phosphatidic Acids] Phosphatidic Acids results in increased secretion of TNF protein
[[[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of Phosphatidylcholines] which results in increased chemical synthesis of phosphatidylcholine hydroperoxide; [[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of Phosphatidylcholines; Edetic Acid inhibits the reaction [[[[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of Phosphatidylcholines] which results in increased chemical synthesis of phosphatidylcholine hydroperoxide]; Penicillamine inhibits the reaction [[[[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of Phosphatidylcholines] which results in increased chemical synthesis of phosphatidylcholine hydroperoxide]; Trientine inhibits the reaction [[[[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of Phosphatidylcholines] which results in increased chemical synthesis of phosphatidylcholine hydroperoxide]
[silybin co-treated with Phosphatidylcholines co-treated with Vitamin E] inhibits the reaction [Dimethylnitrosamine results in increased expression of COL1A1 mRNA]
GPX4 mutant form promotes the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite]; GPX4 protein inhibits the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite]
Phosphatidylcholines results in increased expression of IL1B mRNA Phosphatidylcholines results in increased expression of and results in increased secretion of IL1B protein
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of Phosphatidylcholines LIPC gene mutant form results in increased abundance of Phosphatidylcholines
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of Phosphatidylcholines LIPG gene mutant form results in increased abundance of Phosphatidylcholines
[LTF protein co-treated with Phosphatidylcholines co-treated with Phytosterols] inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]
[silybin co-treated with Phosphatidylcholines co-treated with Vitamin E] inhibits the reaction [Dimethylnitrosamine results in increased expression of MMP2 mRNA]
PAFAH1B1 protein promotes the reaction [Terbutaline results in increased secretion of Phosphatidylcholines]; PAFAH1B1 protein promotes the reaction [Tetradecanoylphorbol Acetate results in increased secretion of Phosphatidylcholines] PAFAH1B1 protein results in increased secretion of Phosphatidylcholines
[SFTPA1 protein polymorphism binds to SFTPA2 protein polymorphism] inhibits the reaction [Adenosine Triphosphate results in increased secretion of Phosphatidylcholines]; Ozone inhibits the reaction [[SFTPA1 protein polymorphism binds to SFTPA2 protein polymorphism] inhibits the reaction [Adenosine Triphosphate results in increased secretion of Phosphatidylcholines]]; Ozone inhibits the reaction [SFTPA1 protein polymorphism inhibits the reaction [Adenosine Triphosphate results in increased secretion of Phosphatidylcholines]]
[silybin co-treated with Phosphatidylcholines co-treated with Vitamin E] inhibits the reaction [Dimethylnitrosamine results in increased expression of TGFB1 mRNA]
[silybin co-treated with Phosphatidylcholines co-treated with Vitamin E] inhibits the reaction [Dimethylnitrosamine results in increased expression of TIMP1 mRNA]
GPX4 mutant form promotes the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite]; GPX4 protein inhibits the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite]; NOX4 mutant form inhibits the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite]; PAFAH2 inhibits the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite] Phosphatidylcholines results in increased expression of TNF mRNA [LTF protein co-treated with Phosphatidylcholines co-treated with Phytosterols] inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Phosphatidylcholines results in increased expression of and results in increased secretion of TNF protein
calpeptin inhibits the reaction [dehydroeburicoic acid promotes the reaction [MAP1LC3B protein binds to phosphatidylethanolamine]]; dehydroeburicoic acid promotes the reaction [MAP1LC3B protein binds to phosphatidylethanolamine]
NCS1 protein results in increased phosphorylation of phosphatidylinositol 4-phosphate wortmannin inhibits the reaction [NCS1 protein results in increased phosphorylation of phosphatidylinositol 4-phosphate]
[phosphatidylinositol dimannoside analog co-treated with Thioglycolates] results in increased expression of IL6 protein; phosphatidylinositol dimannoside analog inhibits the reaction [[Lipopolysaccharides co-treated with Thioglycolates] results in increased expression of IL6 protein]; phosphatidylinositol dimannoside analog promotes the reaction [[Lipopolysaccharides co-treated with Thioglycolates] results in increased expression of IL6 protein]; TLR4 gene mutant form inhibits the reaction [[phosphatidylinositol dimannoside analog co-treated with Thioglycolates] results in increased expression of IL6 protein]
TLR4 gene mutant form inhibits the reaction [[phosphatidylinositol dimannoside analog co-treated with Thioglycolates] results in increased expression of IL6 protein]
browse the term
